Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Drug Saf. 2012 May;11(3):473-85. doi: 10.1517/14740338.2012.676639. Epub 2012 Apr 3.

Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.

Author information

1
Infectious Diseases Unit, Hospital de la Santa Creu I Sant Pau, Univeristat Autònoma de Barcelona, Av. Sant Antoni Mª Claret, 167, 08025 Barcelona, Spain.

Abstract

INTRODUCTION:

The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries. This review is intended to assess the benefits and risks in terms of safety of d4T + 3TC-based combination antiretroviral therapy (ART) for the treatment of HIV-1 infection.

AREAS COVERED:

The most relevant papers related to the safety of d4T + 3TC-based ART were selected and summarized.

EXPERT OPINION:

In industrialized countries, the 3TC + d4T combination is not recommended for initial therapy because of long-term metabolic toxicities associated with d4T. In developing countries, it may have a role in the treatment of HIV-infected patients if there is no other chance for starting antiretroviral therapy.

PMID:
22468613
DOI:
10.1517/14740338.2012.676639
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center